Developments in immunosuppression
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00080659" target="_blank" >RIV/00023001:_____/21:00080659 - isvavai.cz</a>
Výsledek na webu
<a href="https://journals.lww.com/co-transplantation/Fulltext/2021/02000/Developments_in_immunosuppression.14.aspx" target="_blank" >https://journals.lww.com/co-transplantation/Fulltext/2021/02000/Developments_in_immunosuppression.14.aspx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MOT.0000000000000844" target="_blank" >10.1097/MOT.0000000000000844</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Developments in immunosuppression
Popis výsledku v původním jazyce
PURPOSE OF REVIEW: In this review, we discuss achievements in immunosuppression in kidney transplant recipients published at last 18 months. RECENT FINDINGS: Results of recent trials with everolimus in low-risk primary kidney transplant recipients suggest that lowTAC/EVR combination is noninferior and CMV and BKV viral infections are less frequent to standTAC/MPA. Iscalimab monoclonal antibody, which prevents CD40 to CD154 binding, has just recently entered phase II clinical studies in kidney transplantation. Eculizumab, anti-C5 monoclonal antobody was recently shown to improve outcomes in DSA+ living-donor kidney transplant recipients requiring pretransplant desensitization because of crossmatch positivity. Proximal complement C1 inhibition in patients with antibody-mediated rejection was studied in several phase I trials. SUMMARY: Recent knowledge creates a path towards future immunosuppression success in sensitized recipients and in those in high risk of viral infections or CNI nephrotoxicity. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Název v anglickém jazyce
Developments in immunosuppression
Popis výsledku anglicky
PURPOSE OF REVIEW: In this review, we discuss achievements in immunosuppression in kidney transplant recipients published at last 18 months. RECENT FINDINGS: Results of recent trials with everolimus in low-risk primary kidney transplant recipients suggest that lowTAC/EVR combination is noninferior and CMV and BKV viral infections are less frequent to standTAC/MPA. Iscalimab monoclonal antibody, which prevents CD40 to CD154 binding, has just recently entered phase II clinical studies in kidney transplantation. Eculizumab, anti-C5 monoclonal antobody was recently shown to improve outcomes in DSA+ living-donor kidney transplant recipients requiring pretransplant desensitization because of crossmatch positivity. Proximal complement C1 inhibition in patients with antibody-mediated rejection was studied in several phase I trials. SUMMARY: Recent knowledge creates a path towards future immunosuppression success in sensitized recipients and in those in high risk of viral infections or CNI nephrotoxicity. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30213 - Transplantation
Návaznosti výsledku
Projekt
<a href="/cs/project/NV19-06-00031" target="_blank" >NV19-06-00031: Operační tolerance po transplantaci ledviny</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Current opinion in organ transplantation
ISSN
1087-2418
e-ISSN
—
Svazek periodika
26
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
6
Strana od-do
91-96
Kód UT WoS článku
000612851700013
EID výsledku v databázi Scopus
2-s2.0-85099113527